Business Information
The group's principal activities are to discover, develop and commercialize novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. The group has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. The group has produced novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular diseases, fungal diseases, inflammatory diseases, high blood pressure and asthma.
|
|
Name |
Title
|
Email
|
| James Sabry | Co - Founder, Executive Chmn. | N/A | | Sharon Surrey-Barbari | Sr. VP - Finance, CFO | N/A | | Andrew Wolff | Chief Medical Officer, Sr. VP - Clinical Research, Development | N/A | | David Cragg | VP - Human Resources | N/A | | David Morgans | Sr. VP - Preclinical Research, Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 3,127 | (57,115) | | 2005 | 8,912 | (42,252) | | 2004 | 13,442 | (37,198)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
